Martin Wawruch1, Dusan Zatko2, Gejza Wimmer3, Jan Luha4, Lenka Kuzelova3, Peter Kukumberg5, Jan Murin6, Adam Hloska7,8, Tomas Tesar9, Zoltan Kallay3, Rashmi Shah10. 1. Faculty of Medicine, Institute of Pharmacology and Clinical Pharmacology, Comenius University, Sasinkova, 4, 811 08, Bratislava, Slovakia. martin.wawruch@gmail.com. 2. General Health Insurance Company, Bratislava, Slovakia. 3. Faculty of Medicine, Institute of Pharmacology and Clinical Pharmacology, Comenius University, Sasinkova, 4, 811 08, Bratislava, Slovakia. 4. Department of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Bratislava, Slovakia. 5. 2nd Department of Neurology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. 6. 1st Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia. 7. Ministry of Health of the Slovak Republic, Bratislava, Slovakia. 8. Department of Pharmacology, Jessenius Faculty of Medicine in Martin, Comenius University, Bratislava, Slovakia. 9. Department of Organisation and Management of Pharmacy, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia. 10. , Gerrards Cross, UK.
Abstract
OBJECTIVES: This study investigated the extent of, and patient-related characteristics for, non-persistence with antiplatelet therapy during follow-up in elderly patients after their first ischaemic non-cardioembolic stroke. METHODS: A database of the largest health insurance provider in the Slovak Republic was used to assemble the study cohort of 4319 patients (56.8% were women) aged ≥65 years in whom antiplatelet therapy was initiated following a hospital-based diagnosis of stroke during the period 1 January 2010 to 31 December 2010. Patients were followed for 3 years from the date on which the first prescription of antiplatelet medication was recorded. Patients with a 6-month treatment gap without antiplatelet medication prescription were designated as non-persistent, and the Cox proportional hazards model was used to identify predictors of non-persistence. RESULTS: At the end of the 3-year follow-up period, 1184 (27.4%) patients were considered non-persistent with antiplatelet medication. In 1244 (28.8%) patients, a switch in the use of a particular antiplatelet drug was registered during this follow-up period. Female sex (hazard ratio [HR] 1.25) was associated with increased risk of non-persistence. In contrast, factors associated with lower probability of non-persistence were age ≥75 years (HR 0.72), switch in antiplatelet medication use (HR 0.76), diabetes mellitus (HR 0.81), dementia (HR 0.69) and epilepsy (HR 0.69). CONCLUSIONS: Our results suggest that women, patients aged <75 years, and patients without certain comorbid conditions may need improved assistance in secondary prevention management after an ischaemic stroke.
OBJECTIVES: This study investigated the extent of, and patient-related characteristics for, non-persistence with antiplatelet therapy during follow-up in elderly patients after their first ischaemic non-cardioembolic stroke. METHODS: A database of the largest health insurance provider in the Slovak Republic was used to assemble the study cohort of 4319 patients (56.8% were women) aged ≥65 years in whom antiplatelet therapy was initiated following a hospital-based diagnosis of stroke during the period 1 January 2010 to 31 December 2010. Patients were followed for 3 years from the date on which the first prescription of antiplatelet medication was recorded. Patients with a 6-month treatment gap without antiplatelet medication prescription were designated as non-persistent, and the Cox proportional hazards model was used to identify predictors of non-persistence. RESULTS: At the end of the 3-year follow-up period, 1184 (27.4%) patients were considered non-persistent with antiplatelet medication. In 1244 (28.8%) patients, a switch in the use of a particular antiplatelet drug was registered during this follow-up period. Female sex (hazard ratio [HR] 1.25) was associated with increased risk of non-persistence. In contrast, factors associated with lower probability of non-persistence were age ≥75 years (HR 0.72), switch in antiplatelet medication use (HR 0.76), diabetes mellitus (HR 0.81), dementia (HR 0.69) and epilepsy (HR 0.69). CONCLUSIONS: Our results suggest that women, patients aged <75 years, and patients without certain comorbid conditions may need improved assistance in secondary prevention management after an ischaemic stroke.
Authors: S Johnston; S W Janning; G P Haas; K L Wilson; D M Smith; G Reckard; S-P Quan; S Bukofzer Journal: Int J Clin Pract Date: 2012-11 Impact factor: 2.503
Authors: Joyce A Cramer; Anuja Roy; Anita Burrell; Carol J Fairchild; Mahesh J Fuldeore; Daniel A Ollendorf; Peter K Wong Journal: Value Health Date: 2008 Jan-Feb Impact factor: 5.725
Authors: Robert W V Flynn; Thomas M MacDonald; Gordon D Murray; Ronald S MacWalter; Alexander S F Doney Journal: Cerebrovasc Dis Date: 2012-01-18 Impact factor: 2.762
Authors: Martin Wawruch; Dusan Zatko; Gejza Wimmer; Jan Luha; Sona Wimmerova; Petra Matalova; Peter Kukumberg; Jan Murin; Tomas Tesar; Beata Havelkova; Rashmi Shah Journal: Clin Drug Investig Date: 2017-11 Impact factor: 2.859
Authors: Daniela Rohde; Niamh A Merriman; Frank Doyle; Kathleen Bennett; David Williams; Anne Hickey Journal: PLoS One Date: 2017-12-08 Impact factor: 3.240